C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 207/08 (2006.01) A61K 31/40 (2006.01) A61K 31/4025 (2006.01) A61P 25/00 (2006.01) C07D 207/06 (2006.01) C07D 405/04 (2006.01)
Patent
CA 2749309
In various embodiments, the present invention provides cycloalkyl pyrrolidine compounds and methods for their use in the treatment and/or prevention of various diseases, conditions and syndromes, including central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.
Dans divers modes de réalisation, la présente invention concerne des composés de cycloalkylpyrrolidine et des procédés pour les utiliser dans le traitement et/ou la prévention de diverses maladies, états et syndromes, notamment des affections du système nerveux central (SNC), comme la dépression, l'anxiété, la schizophrénie et les troubles du sommeil, ainsi que des procédés pour leur synthèse. L'invention concerne également des compositions pharmaceutiques contenant les composés de l'invention, ainsi que des procédés d'inhibition de la réabsorption de monoamines endogènes, comme la dopamine, la sérotonine et la norépinéphrine, par la fente synaptique, et des procédés de modulation d'un ou plusieurs transporteurs de monoamines.
Ma Jianguo
Shao Liming
Osler Hoskin & Harcourt Llp
Sunovion Pharmaceuticals Inc.
LandOfFree
Pyrrolidine triple reuptake inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrrolidine triple reuptake inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolidine triple reuptake inhibitors will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1364451